Context Therapeutics Inc — Quarterly Cash Flow (NASDAQ:CNTX) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Total assets 98.13 M92.97 M87.15 M79.23 M68.49 M Total liabilities 2.86 M1.98 M4.61 M6.06 M8.02 M Total equity 95.27 M90.98 M82.54 M73.17 M60.47 M Total liabilities & shareholders' equities 98.13 M92.97 M87.15 M79.23 M68.49 M Total debt ————— Net debt —————

Nouvelles

Pourquoi les actions de GH Research sont échangées à la hausse de 18% ; Voici 20 actions qui bougent avant l'ouverture du marché | Benzinga France

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - BioAtla (NASDAQ:BCAB), ChowChow Cloud Internatio (AMEX:CHOW)

This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - AirJoule Technologies (NASDAQ:AIRJ), BlackSky Technology (NYSE:BKSY)

Step Pharma appoints Karen Smith as chief medical officer

This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Context Therapeutics (NASDAQ:CNTX), Absci (NASDAQ:ABSI)

Rare Stock Picks In June 2025 - From 26 Discerning Analysts

Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX)

Citizens JMP affirms $4 price target on Context Therapeutics stock

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Citizens JMP highlights key ASCO presentations

Centrexion Therapeutics stock hits 52-week low at $0.55

Citizens JMP highlights bispecific antibodies progress